CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2020 Earnings Conference Call May 7, 2020 5:00 PM ET Company Participants Christopher Keenan - VP, IR Sean McCarthy - President, CEO, and Chairman Carlos Campoy - SVP and CFO Conference Call Participants Christopher Marai - Nomura Instinet Terence Flynn - Goldman Sachs Robert Burns - H.C. Wainwright Boris Peaker - Cowen Mara Goldstein - Mizuho Etzer Darout - Guggenheim Securities Joseph Catanzaro - Piper Sandler Mohit Bansal - Citigroup Biren Amin - Jefferies Opera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 | --- | --- | --- | |---------------------------------------------------------------------------------------|----------------------------------------------- ...

REIMAGINING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER Cowen and Company 40th Annual Health Care Conference MARCH 2020 © 2020 CytomX Therapeutics, Inc. Forward Looking Statement This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, precl ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2019 Results Earnings Conference Call February 27, 2020 5:00 PM ET Company Participants Christopher Keenan - VP, IR Sean McCarthy - President and CEO, and Chairman Amy Peterson - EVP and Chief Development Officer Robin Knifsend - VP, Finance Conference Call Participants Christopher Marai - Nomura Instinet Mara Goldstein - Mizuho Securities Robert Burns - H.C. Wainwright Etzer Darout - Guggenheim Biren Amin - Jefferies Joe Catanzaro - Piper Sandler Varun Kumar - Can ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |---------------------------------------------------------------------------------------------------|------------------------------------------------------------------------- ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2019 Earnings Conference Call November 7, 2019 5:00 PM ET Company Participants Christopher Keenan - VP of IR Sean McCarthy - President, CEO Robin Knifsend - VP of Finance Amy Peterson - Chief Development Officer Conference Call Participants Varun Kumar - Cantor Fitzgerald Mohit Bansal - Citi Mara Goldstein - Mizuho Securities Boris Peaker - Cowen & Company Biren Amin - Jefferies Terence Flynn - Goldman Sachs Robert Burns - H.C. Wainwright Operator Good day, ladies ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------|----------- ...

REIMAGINING THERAPEUTIC ANTIBODIES H.C. Wainwright 21st Annual Global Investment Conference SEPTEMBER 10, 2019 © 2019 CytomX Therapeutics, Inc. 1 Forward Looking Statement This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, preclinical and cli ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 27-3521219 (State or other jurisdiction of incorporation or organiz ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 | --- | --- | |---------------------------------------------------------------------------------------|----------------------------------------------------- ...